Michela Boi

1.4k total citations
17 papers, 475 citations indexed

About

Michela Boi is a scholar working on Molecular Biology, Pathology and Forensic Medicine and Oncology. According to data from OpenAlex, Michela Boi has authored 17 papers receiving a total of 475 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Molecular Biology, 7 papers in Pathology and Forensic Medicine and 4 papers in Oncology. Recurrent topics in Michela Boi's work include Protein Degradation and Inhibitors (9 papers), Lymphoma Diagnosis and Treatment (7 papers) and Multiple Myeloma Research and Treatments (4 papers). Michela Boi is often cited by papers focused on Protein Degradation and Inhibitors (9 papers), Lymphoma Diagnosis and Treatment (7 papers) and Multiple Myeloma Research and Treatments (4 papers). Michela Boi collaborates with scholars based in Switzerland, Italy and United States. Michela Boi's co-authors include Giorgio Inghirami, Francesco Bertoni, Emanuele Zucca, Esteban Cvitkovic, Ivo Kwee, Andrea Rinaldi, Anastasios Stathis, María E. Riveiro, Eugenio Gaudio and Maurilio Ponzoni and has published in prestigious journals such as Nature Communications, Blood and Cancer Research.

In The Last Decade

Michela Boi

16 papers receiving 467 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Michela Boi Switzerland 7 362 159 120 113 50 17 475
Britta Lamottke Germany 7 300 0.8× 84 0.5× 151 1.3× 105 0.9× 48 1.0× 8 420
Ruta Grebliunaite United States 5 332 0.9× 278 1.7× 117 1.0× 47 0.4× 44 0.9× 6 623
Lenka Bešše Switzerland 12 248 0.7× 186 1.2× 121 1.0× 57 0.5× 66 1.3× 39 399
Ellen Ingalla United States 5 241 0.7× 127 0.8× 126 1.1× 49 0.4× 29 0.6× 12 339
Zohar Sachs United States 12 246 0.7× 138 0.9× 83 0.7× 42 0.4× 82 1.6× 36 383
Santhana G.T. Devaraj United States 5 511 1.4× 212 1.3× 160 1.3× 44 0.4× 29 0.6× 12 572
Jonathan A. Schumacher United States 11 137 0.4× 89 0.6× 62 0.5× 122 1.1× 49 1.0× 25 374
Mio Yamamoto‐Sugitani Japan 10 219 0.6× 129 0.8× 94 0.8× 91 0.8× 65 1.3× 18 363
Patricia Kropf United States 9 193 0.5× 138 0.9× 59 0.5× 42 0.4× 32 0.6× 26 341
Taku Tsukamoto Japan 10 162 0.4× 99 0.6× 116 1.0× 83 0.7× 32 0.6× 50 304

Countries citing papers authored by Michela Boi

Since Specialization
Citations

This map shows the geographic impact of Michela Boi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michela Boi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michela Boi more than expected).

Fields of papers citing papers by Michela Boi

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michela Boi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michela Boi. The network helps show where Michela Boi may publish in the future.

Co-authorship network of co-authors of Michela Boi

This figure shows the co-authorship network connecting the top 25 collaborators of Michela Boi. A scholar is included among the top collaborators of Michela Boi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michela Boi. Michela Boi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
Novazzi, Federica, Alessia Lai, Michela Boi, et al.. (2025). Large norovirus GII.17 outbreak in a school in Northern Italy: A novel emerging sublineage within an emerging genotype?. International Journal of Infectious Diseases. 162. 108185–108185.
2.
Boi, Michela, Maria Chiara Todaro, Valentina Vurchio, et al.. (2016). Therapeutic efficacy of the bromodomain inhibitor OTX015/MK-8628 in ALK-positive anaplastic large cell lymphoma: an alternative modality to overcome resistant phenotypes. Oncotarget. 7(48). 79637–79653. 19 indexed citations
3.
Pizzi, Marco, Michela Boi, Francesco Bertoni, & Giorgio Inghirami. (2016). Emerging therapies provide new opportunities to reshape the multifaceted interactions between the immune system and lymphoma cells. Leukemia. 30(9). 1805–1815. 23 indexed citations
4.
Boi, Michela, Eugenio Gaudio, Paola Bonetti, et al.. (2015). The BET Bromodomain Inhibitor OTX015 Affects Pathogenetic Pathways in Preclinical B-cell Tumor Models and Synergizes with Targeted Drugs. Clinical Cancer Research. 21(7). 1628–1638. 214 indexed citations
5.
Pan, Heng, Yanwen Jiang, Michela Boi, et al.. (2015). Epigenomic evolution in diffuse large B-cell lymphomas. Nature Communications. 6(1). 6921–6921. 94 indexed citations
6.
Boi, Michela, Emanuele Zucca, Giorgio Inghirami, & Francesco Bertoni. (2015). Advances in understanding the pathogenesis of systemic anaplastic large cell lymphomas. British Journal of Haematology. 168(6). 771–783. 38 indexed citations
7.
Gaudio, Eugenio, Elena Bernasconi, Ivo Kwee, et al.. (2014). Abstract 5528: The BET Bromodomain inhibitor OTX015 targets the NFKB, TLR and JAK/STAT pathways and shows pre-clinical activity as single agent and in combination in mature B-cell tumors. Cancer Research. 74(19_Supplement). 5528–5528. 1 indexed citations
8.
Vázquez, Ramiro, Lucile Astorgues‐Xerri, Mohamed Békradda, et al.. (2014). Abstract 5530: OTX015, a novel pan BET-BRD inhibitor is active in non-small-cell lung cancer (NSCLC) cell lines bearing the fusion protein EML4-ALK. Cancer Research. 74(19_Supplement). 5530–5530. 1 indexed citations
9.
Todaro, Maria Chiara, Michela Boi, Valentina Vurchio, et al.. (2014). Abstract 5531: OTX015, a novel BET inhibitor, is a promising anticancer agent for multiple myeloma. Cancer Research. 74(19_Supplement). 5531–5531. 3 indexed citations
10.
Boi, Michela, Emanuele Zucca, Giorgio Inghirami, & Francesco Bertoni. (2014). PRDM1/BLIMP1: a tumor suppressor gene in B and T cell lymphomas. Leukemia & lymphoma. 56(5). 1223–1228. 53 indexed citations
11.
Crescenzo, Ramona, Francesco Abate, Elena Lasorsa, et al.. (2014). Convergent Mutations and New Kinase Fusions Lead to Oncogenic STAT3 Activation in Anaplastic Large Cell Lymphoma. Blood. 124(21). 781–781. 1 indexed citations
12.
Gaudio, Eugenio, Ivo Kwee, Elena Bernasconi, et al.. (2013). Abstract A119: The BET-bromodomain inhibitor OTX015 shows synergism with several anticancer agents in preclinical models of diffuse large B-cell lymphoma (DLBCL).. Molecular Cancer Therapeutics. 12(11_Supplement). A119–A119. 2 indexed citations
13.
Boi, Michela, Maria Chiara Todaro, Valentina Vurchio, et al.. (2013). Abstract A219: OTX015, a bromodomain and extraterminal inhibitor, represents a novel agent for ALK positive anaplastic large cell lymphoma.. Molecular Cancer Therapeutics. 12(11_Supplement). A219–A219. 3 indexed citations
14.
Boi, Michela, Anastasios Stathis, Emanuele Zucca, Giorgio Inghirami, & Francesco Bertoni. (2012). Genetic alterations in systemic nodal and extranodal non‐cutaneous lymphomas derived from mature T cells and natural killer cells. Cancer Science. 103(8). 1397–1404. 4 indexed citations
15.
Bonetti, Paola, Michela Boi, Maurilio Ponzoni, et al.. (2012). The Brd-Inhibitor OTX015 Is Active in Pre-Clinical Models of Mature B-Cell Lymphoid Tumors. Blood. 120(21). 1657–1657. 3 indexed citations
16.
Boi, Michela, Paola Bonetti, Maurilio Ponzoni, et al.. (2012). The Brd-Inhibitor OTX015 Shows Pre-Clinical Activity in Anaplastic Large T-Cell Lymphoma (ALCL). Blood. 120(21). 4872–4872. 6 indexed citations
17.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Britta Lamottke Breakdown of academic impact, for papers by Ruta Grebliunaite Breakdown of academic impact, for papers by Lenka Bešše Breakdown of academic impact, for papers by Ellen Ingalla Breakdown of academic impact, for papers by Zohar Sachs Breakdown of academic impact, for papers by Santhana G.T. Devaraj Breakdown of academic impact, for papers by Jonathan A. Schumacher Breakdown of academic impact, for papers by Mio Yamamoto‐Sugitani Breakdown of academic impact, for papers by Patricia Kropf Breakdown of academic impact, for papers by Taku Tsukamoto
Rankless by CCL
2026